Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids: a mechanistic analysis

BACKGROUND: Community-based clinical trials of the inhaled corticosteroid budesonide in early COVID-19 have shown improved patient outcomes. We aimed to understand the inflammatory mechanism of budesonide in the treatment of early COVID-19. METHODS: The STOIC trial was a randomised, open label, para...

Descripción completa

Detalles Bibliográficos
Autores principales: Baker, Jonathan R, Mahdi, Mahdi, Nicolau, Dan V, Ramakrishnan, Sanjay, Barnes, Peter J, Simpson, Jodie L, Cass, Steven P, Russell, Richard E K, Donnelly, Louise E, Bafadhel, Mona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8989397/
https://www.ncbi.nlm.nih.gov/pubmed/35397798
http://dx.doi.org/10.1016/S2213-2600(22)00002-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8989397/
https://www.ncbi.nlm.nih.gov/pubmed/35397798
http://dx.doi.org/10.1016/S2213-2600(22)00002-9

Ejemplares similares